Application of combined detection of tumor markers, serum pepsinogen, and gastrin-17 in thediagnosis of gastric cancer_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

XIONG Shimeng ^1,2 , XU Zipeng ¹ , NAN Yaqiang ¹ , CHEN Peng ³ , LI Hongtao ² ,  LIU Hongbin ^1,2

1. The Second Clinical Medical College of Lanzhou University, Lanzhou 730030, P. R. China;
2. The Department of General Surgery, Joint Logistic Support Force 940 Hospital of the People's Liberation Army, Lanzhou 730050, P. R. China;
3. The Clinical Medical College of Gansu University of Traditional Chinese Medicine, Lanzhou 730000, P. R. China;

Corresponding?author：

LIU Hongbin, Email: liuhongbin999@163.com

Keywords：

gastric cancer; carbohydrate antigen 19-9; carbohydrate antigen 72-4; carcinoembryonic antigen; pepsinogen; gastrin-17; combined detection

DOI：

10.7507/1007-9424.201903092

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To explore the application value of the combined detection of CA19-9, CA72-4, carcinoembryonic antigen (CEA), serum pepsinogen Ⅰ(PGⅠ), serum pepsinogen Ⅱ(PGⅡ), ratio of PGⅠ and PGⅡ (PGR), and gastrin-17 (G17) in the diagnosis of gastric cancer.Methods One hundred cases of gastric cancer admitted to the Joint Logistic Support Force 940 Hospital of the People’s Liberation Army from January 2016 to August 2018 were respectively collected as the observation group, 110 cases of benign gastric lesions as the control group during the same period, the levels of serum CA19-9, CA72-4, CEA, PGⅠ, PGⅡ, PGR, and G17 were tested among patients in the two groups, the diagnostic value of single and combined detection (included CA19-9, CA72-4, CEA, PGⅠ, PGⅡ, PGR, and G17) were explored.Results The levels of CA19-9, CA72-4, CEA, and G17 in the observation group were higher than those of the control group (P<0.05), the levels of PGⅠ and PGR were lower than those of the control group (P<0.05). The positive detection rates of CA19-9, CA72-4, CEA, G17, PGⅠ, PGR, and combined detection in the observation group were all higher than those of the control group (P<0.05). The sensitivity and accuracy of the combined detection in the diagnosis of gastric cancer were higher than that of single serum index (P<0.05). The levels of serum CA19-9, CA72-4, CEA, and G17 in the patients of Ⅲ+Ⅳ period, low and moderate degree of differentiation, the tumor diameter was larger than five centimeters, signet-ring cell carcinoma, and distance metastasis of gastric cancer patients were on the high side compared with Ⅰ+Ⅱ period, high differentiation, the tumor diameter was less than or equal to five centimeters, glandular cancer, and no distance metastasis of gastric cancer patients, as well as the levels of serum PGⅠ and PGR on the low side (P<0.05).Conclusion The combined detection of CA19-9, CA72-4, CEA, PGⅠ, PGⅡ, PGR, and G17 can effectively improve the diagnose rate of gastric cancer, and they are closely related to the pathological characteristics of gastriccancer patients.

Citation： XIONG Shimeng, XU Zipeng, NAN Yaqiang, CHEN Peng, LI Hongtao, LIU Hongbin. Application of combined detection of tumor markers, serum pepsinogen, and gastrin-17 in thediagnosis of gastric cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2019, 26(8): 923-928. doi: 10.7507/1007-9424.201903092 Copy

1.	楊勵勵. 2010-2013 年錦州市居民惡性腫瘤死亡原因分析. 中國衛生工程學, 2016, 15(1): 75-76.
2.	黃淼. 幽門螺桿菌在慢性胃病患者中感染的流行病學調查及影響其根除的相關因素. 中國衛生工程學, 2017, 16(4): 480-482.
3.	韋志鵑, 張曉云. 血清胃功能檢測在早期胃癌篩查中的臨床應用研究. 國際檢驗醫學雜志, 2017, 38(16): 2240-2242.
4.	Sun Z, Zhang N. Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy. World J Surg Oncol, 2014, 12: 397.
5.	孫潔, 孟祥軍. 血清 CA199、CEA、CA125、CA724 聯合檢測在胃癌診斷中的價值. 中國實驗診斷學, 2014, 18(12): 1936-1939.
6.	Thapa A, Soares AC, Soares JC, et al. Carbon nanotube matrix for highly sensitive biosensors to detect pancreatic cancer biomarker CA19-9. ACS Appl Mater Interfaces, 2017, 9(31): 25878-25886.
7.	董曉微, 崔學強, 張俊華, 等. 血清腫瘤標志物 CA19-9、CA72-4、CEA、PGⅠ 聯合檢測對胃癌的診斷及預后價值分析. 國際檢驗醫學雜志, 2018, 39(17): 2185-2188.
8.	楊衛. 血清腫瘤標志物 CEA、CA19-9、CA242、CA724 聯合檢測對胃癌的診斷效果分析. 數理醫藥學雜志, 2018, 31(1): 47-48.
9.	Shimada H, Noie T, Ohashi M, et al. Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association. Gastric Cancer, 2014, 17(1): 26-33.
10.	梁紅. CA199、CEA 對判斷胃癌轉移與預后的應用價值. 中國衛生工程學, 2018, 17(3): 421-423.
11.	Deng K, Yang L, Hu B, et al. The prognostic significance of pretreatment serum CEA levels in gastric cancer: a meta-analysis including 14 651 patients. PLoS One, 2015, 10(4): e0124151.
12.	祝占奎, 黃澤平, 周亞雄, 等. 血清 CEA 及 CA19-9 水平與胃癌預后的關系. 包頭醫學院學報, 2018, 34(2): 10-12.
13.	曹曉莉, 張金業. 胃癌患者術后腫瘤標志物水平與臨床預后的關系研究. 檢驗醫學與臨床, 2013, 10(16): 2133-2135.
14.	呂賓. 重視胃癌的篩查和早期診斷. 浙江醫學, 2018, 40(14): 1521-1522, 1543.
15.	Tu H, Sun L, Dong X, et al. Temporal changes in serum biomarkers and risk for progression of gastric precancerous lesions: a longitudinal study. Int J Cancer, 2015, 136(2): 425-434.
16.	Yanaoka K, Oka M, Mukoubayashi C, et al. Cancer high-risk subjects identified by serum pepsinogen tests: outcomes after10-year follow-up in asymptomatic middle-aged males. Cancer Epidemiol Biomarkers Prev, 2008, 17(4): 838-845.
17.	陳卿奇, 羊文芳, 吳素江, 等. 血清胃蛋白酶原及胃泌素-17 水平與胃癌的相關性研究. 重慶醫學, 2016, 45(35): 4938-4941, 4944.
18.	高洪亮, 李寧, 張清祿. 血清 PGⅠ、PGⅡ 及 G-17 檢測在胃癌及萎縮性胃炎中的診斷價值分析. 癌癥進展, 2017, 15(6): 654-656.
19.	Mishra P, Senthivinayagam S, Rana A, et al. Glycogen synthase kinase-3beta regulates snail and beta-catenin during gastrin-induced migration of gastric cancer cells. J Mol Signal, 2010, 5: 9.
20.	沈晨. 血清 PGⅠ、PGⅡ 及 G17 檢測在早期胃癌篩查中的應用效果. 臨床醫學研究與實踐, 2018, 3(27): 104-105.
21.	黃道桂, 任傳路, 虞紅艷, 等. 血清 PGⅠ, PGⅡ, TK1, TSGF, CEA 與 CA724 聯合檢測在胃癌診斷中的應用價值. 現代檢驗醫學雜志, 2015, 30(1): 101-104.
22.	李迎今, 蘇軍燕, 徐長妍. 血清 CEA、PGR、G-17 檢測在胃癌診斷中的價值分析. 中國實驗診斷學, 2017, 21(9): 1498-1501.
23.	Kikuchi R, Abe Y, Iijima K, et al. Low serum levels of pepsinogen and gastrin 17 are predictive of extensive gastric atrophy with high-risk of early gastric cancer. Tohoku J Exp Med, 2011, 223(1): 35-44.
24.	付愛琳, 張俊璇, 于琪力, 等. 血清胃泌素-17 聯合胃蛋白酶原檢測對胃癌診斷價值的臨床研究. 世界最新醫學信息文摘, 2018, 18(86): 155.
25.	黃樹華, 張輝亮, 梁藝華, 等. CA72-4 與血清胃蛋白酶原比值對胃癌的鑒別診斷意義. 中國實用醫藥, 2018, 13(19): 32-33.

1. 楊勵勵. 2010-2013 年錦州市居民惡性腫瘤死亡原因分析. 中國衛生工程學, 2016, 15(1): 75-76.
2. 黃淼. 幽門螺桿菌在慢性胃病患者中感染的流行病學調查及影響其根除的相關因素. 中國衛生工程學, 2017, 16(4): 480-482.
3. 韋志鵑, 張曉云. 血清胃功能檢測在早期胃癌篩查中的臨床應用研究. 國際檢驗醫學雜志, 2017, 38(16): 2240-2242.
4. Sun Z, Zhang N. Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy. World J Surg Oncol, 2014, 12: 397.
5. 孫潔, 孟祥軍. 血清 CA199、CEA、CA125、CA724 聯合檢測在胃癌診斷中的價值. 中國實驗診斷學, 2014, 18(12): 1936-1939.
6. Thapa A, Soares AC, Soares JC, et al. Carbon nanotube matrix for highly sensitive biosensors to detect pancreatic cancer biomarker CA19-9. ACS Appl Mater Interfaces, 2017, 9(31): 25878-25886.
7. 董曉微, 崔學強, 張俊華, 等. 血清腫瘤標志物 CA19-9、CA72-4、CEA、PGⅠ 聯合檢測對胃癌的診斷及預后價值分析. 國際檢驗醫學雜志, 2018, 39(17): 2185-2188.
8. 楊衛. 血清腫瘤標志物 CEA、CA19-9、CA242、CA724 聯合檢測對胃癌的診斷效果分析. 數理醫藥學雜志, 2018, 31(1): 47-48.
9. Shimada H, Noie T, Ohashi M, et al. Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association. Gastric Cancer, 2014, 17(1): 26-33.
10. 梁紅. CA199、CEA 對判斷胃癌轉移與預后的應用價值. 中國衛生工程學, 2018, 17(3): 421-423.
11. Deng K, Yang L, Hu B, et al. The prognostic significance of pretreatment serum CEA levels in gastric cancer: a meta-analysis including 14 651 patients. PLoS One, 2015, 10(4): e0124151.
12. 祝占奎, 黃澤平, 周亞雄, 等. 血清 CEA 及 CA19-9 水平與胃癌預后的關系. 包頭醫學院學報, 2018, 34(2): 10-12.
13. 曹曉莉, 張金業. 胃癌患者術后腫瘤標志物水平與臨床預后的關系研究. 檢驗醫學與臨床, 2013, 10(16): 2133-2135.
14. 呂賓. 重視胃癌的篩查和早期診斷. 浙江醫學, 2018, 40(14): 1521-1522, 1543.
15. Tu H, Sun L, Dong X, et al. Temporal changes in serum biomarkers and risk for progression of gastric precancerous lesions: a longitudinal study. Int J Cancer, 2015, 136(2): 425-434.
16. Yanaoka K, Oka M, Mukoubayashi C, et al. Cancer high-risk subjects identified by serum pepsinogen tests: outcomes after10-year follow-up in asymptomatic middle-aged males. Cancer Epidemiol Biomarkers Prev, 2008, 17(4): 838-845.
17. 陳卿奇, 羊文芳, 吳素江, 等. 血清胃蛋白酶原及胃泌素-17 水平與胃癌的相關性研究. 重慶醫學, 2016, 45(35): 4938-4941, 4944.
18. 高洪亮, 李寧, 張清祿. 血清 PGⅠ、PGⅡ 及 G-17 檢測在胃癌及萎縮性胃炎中的診斷價值分析. 癌癥進展, 2017, 15(6): 654-656.
19. Mishra P, Senthivinayagam S, Rana A, et al. Glycogen synthase kinase-3beta regulates snail and beta-catenin during gastrin-induced migration of gastric cancer cells. J Mol Signal, 2010, 5: 9.
20. 沈晨. 血清 PGⅠ、PGⅡ 及 G17 檢測在早期胃癌篩查中的應用效果. 臨床醫學研究與實踐, 2018, 3(27): 104-105.
21. 黃道桂, 任傳路, 虞紅艷, 等. 血清 PGⅠ, PGⅡ, TK1, TSGF, CEA 與 CA724 聯合檢測在胃癌診斷中的應用價值. 現代檢驗醫學雜志, 2015, 30(1): 101-104.
22. 李迎今, 蘇軍燕, 徐長妍. 血清 CEA、PGR、G-17 檢測在胃癌診斷中的價值分析. 中國實驗診斷學, 2017, 21(9): 1498-1501.
23. Kikuchi R, Abe Y, Iijima K, et al. Low serum levels of pepsinogen and gastrin 17 are predictive of extensive gastric atrophy with high-risk of early gastric cancer. Tohoku J Exp Med, 2011, 223(1): 35-44.
24. 付愛琳, 張俊璇, 于琪力, 等. 血清胃泌素-17 聯合胃蛋白酶原檢測對胃癌診斷價值的臨床研究. 世界最新醫學信息文摘, 2018, 18(86): 155.
25. 黃樹華, 張輝亮, 梁藝華, 等. CA72-4 與血清胃蛋白酶原比值對胃癌的鑒別診斷意義. 中國實用醫藥, 2018, 13(19): 32-33.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Application of combined detection of tumor markers, serum pepsinogen, and gastrin-17 in thediagnosis of gastric cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content